top of page
NTRB-Novel.jpg

Our Pipeline

Our first product and lead platform technology is AVERSA, and abuse deterrent tech which we believe to be applicable to any patch on the market today.

AVERSA™ Fentanyl Abuse Deterrent

AVERSA™ Fentanyl Abuse Deterrent

AVERSA™ Buprenorphine Abuse Deterrent

AVERSA™ Transdermal Technology

AVERSA™ Methylphenidate

AVERSA™ Transdermal Technology

4P Exenatide​

Novel Transdermal

4P FSH

Novel Transdermal

Indication

Chronic Pain

Indication

Chronic Pain

Indication

Attention Deficit Hyperactivity Disorder (ADHD)

Indication

Type 2 Diabetes

Indication

Infertility

Pre-Clinical

Phase 1

FDA Filing

Pre-Clinical

Phase 1

FDA Filing

Pre-Clinical

Phase 1

FDA Filing

Pre-Clinical

Phase 1

FDA Filing

Aversa™ abuse deterrent technology can be incorporated into any transdermal patch that has a risk of abuse.

Get in touch

To find out more, or to enquire about our partnership options, please contact our team who can help find the right solution for your business.

bottom of page